Adbiotech Co., Ltd. 179530

KRX · South Korea · Health Technology

KRW 2,055.00+248.00 (+13.72%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Adbiotech Co., Ltd. 179530

KRX · South Korea · Health Technology

KRW 2,055.00+248.00 (+13.72%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-18.29% · 6MFull-screen chart

Open KRW 1,809.00High KRW 2,125.00Low KRW 1,809.00Close KRW 2,055.00Volume 353.97K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: KRW 1,807.00
Day range: KRW 1,809.00 – KRW 2,125.00
52-week range: KRW 1,300.00 – KRW 4,100.00
Volume: 353.97K
Market cap: KRW 56.24B
Avg. volume (1Y): 271.53K

Performance

1 week

+18.24%

1 month

-19.25%

3 months

-0.48%

6 months

-28.27%

Year to date

-4.20%

1 year

-46.13%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Biotechnology
Country: South Korea
Exchange: KRX
Shares outstanding: 31.12M
Employees: 64
ISIN: KR7179530001
Beta: 0.20

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceApr 22, 2026

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. The collaboration will focus on evaluating combination strategies involving Burixafor (GPC-100) in indications including sickle cell disease (SCD), acute myeloid leukemia (AML), and

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.